FDA warned Pet Essences that its Seizures formula is an unapproved new animal drug marketed to treat seizures in animals.
What happened
FDA reviewed Pet Essences' website from October to November 2024 and found the firm offering a "Seizures" product for animals. The website and labeling claimed the formula reduces seizure frequency, severity, and duration, prevents seizures, and manages active seizures. FDA said these claims make it a drug, and because it lacks approval or index listing, it is an unapproved new animal drug and adulterated.
What FDA found
The product is a drug because it is intended to treat seizures in animals.
FD&C Act § 201(g)(1) [21 U.S.C. § 321(g)(1)]The product is a new animal drug because it is not generally recognized as safe and effective for its labeled use.
FD&C Act § 201(v) [21 U.S.C. § 321(v)]To be legally marketed, a new animal drug needs FDA approval, conditional approval, or index listing.
FD&C Act §§ 512, 571, 572 [21 U.S.C. §§ 360b, 360ccc, 360ccc-1]The product is not approved or index listed, so it is unsafe and adulterated.
FD&C Act § 512(a) [21 U.S.C. § 360b(a)]; § 501(a)(5) [21 U.S.C. § 351(a)(5)]Introducing or delivering the unapproved drug into interstate commerce is prohibited.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]Website claims that the formula reduces, prevents, or manages seizures show the product's intended use as a drug.
FD&C Act § 201(g)(1) [21 U.S.C. § 321(g)(1)]
What FDA wants
FDA asks Pet Essences to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with related documentation. If correction cannot be completed in that time, the company must explain the delay and give a completion date.
Who should pay attention
- pet product brands making disease-treatment claims
- retailers and distributors selling pet seizure products
- veterinarians and pet owners considering unapproved seizure treatments
This is a summary. Read the original letter on fda.gov.